About Michael Yu

Dr. De-Chao Michael Yu (“Dr. Yu”) is the founder, an executive director, the Chairman of the Board and the Chief Executive Officer of the company. Dr. Yu received his doctoral degree in Molecular Genetics from the Chinese Academy of Sciences (Shanghai, China) and completed his post-doctoral training at the University of California San Francisco (San Francisco, USA). Prior to founding Innovent in 2011, Dr. Yu was President, CEO and a member of the Board of Directors of Chengdu Kanghong Biotech from 2006. Previously, Dr. Yu was Vice President of Research and Development at Applied Genetic Technology Corporation (Nasdaq: AGTC) and Calydon, which was acquired by Cell Genesys (Nasdaq: CEGE) in 2001. After the acquisition, he joined Cell Genesys and was responsible for a significant part of the company’s early R&D for the following three years.

Dr. Yu has always aspired to develop and commercialize high-quality biopharmaceuticals that are affordable for ordinary people. He has at present been engaged in innovative research on biopharmaceuticals for more than 20 years, has invented three Class I new drugs and been key to their success. Dr. Yu invented the world’s first commercialized oncolytic virus-based immunotherapeutic product, Oncorine® (recombinant human type-5 adenovirus injection), creating a precedent for the use of viruses to treat tumors. Dr. Yu co-invented and led the development of Langmu® (Conbercept eye injection), and TYVYT® (sintilimab injection), an innovative PD-1 inhibitor for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) , 1L nsq NSCLC, 1L sq NSCLC and 1L HCC.

Dr. Yu is an inventor of over 60 issued patents and patent applications, and has published more than 50 SCI scientific articles and book chapters.